Skip to main content
. Author manuscript; available in PMC: 2010 Oct 1.
Published in final edited form as: Ann Surg Oncol. 2009 Jul 15;16(10):2834–2839. doi: 10.1245/s10434-009-0583-5

Fgure 1.

Fgure 1

The impact of tumor doubling time (TDT) on 5-year post-metastasectomy survival (PMS). Using the median TDT value as the cutoff point (< 61 vs. ≥ 61), TDT ≥ 61 days was significantly associated with better 5-yr PMS (HR = 0.36; 95% CI = 0.08 - 0.78; P = 0.017). Median PMS was 8.7 months for TDT < 61, vs. 20.9 months for TDT ≥ 61.